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ABSTRACT 
An evaluation of the viability and culture characteristics of Bruce Ila abortus 
RB51 vaccine at different storage conditions was conducted to determine optimal 
parameters for storage. The evaluations were done on lyophilized vaccine and liquid 
vaccme. 
Lyophilized Brucella abortus RB51 vaccine was prepared using three 
stabilizing media, World Health Organization (WHO), Lactose Salt (LS), and 
WHO/LS (50/50 v/v). Vaccine was then bottled at lml and 3 ml fill volumes. The 
vaccines were stored at three different storage temperatures of 25°C, 4°C, and-25°C. 
Viability was determined for post-lyophilization survival and every two weeks 
throughout the storage period. There was no significant loss in viability attributed to 
fill volume or stabilizing media on immediate post-lyophilization viability. WHO 
and WHO/LS media were most satisfactory for long-term storage of the lyophilized 
vaccine. Also, at higher storage temperatures there was a more rapid decline in 
viability. 
Liquid Brucella abortus RB51 vaccines were prepared using bottling 
concentrations of 5x109 CFU/ml, lx109 CFU/ml, and 5x108 CFU/ml. The vaccines 
were then distributed in equal amounts and stored at two different storage 
temperatures; viability determinations were conducted at designated sampling times 
throughout the storage period. These three vaccines were then compared to 
determine culture characteristics and viability at these different storage temperatures. 
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A more rapid decline in viability was observed at higher storage temperatures. 
The vaccines bottled at higher cell concentrations maintained higher viability than the 
lower cell concentrations. Brucella abortus RBS I vaccines evaluated maintained 
their original biochemical characteristics at all storage temperatures and bottling 
concentrations examined. 
GENERAL INTRODUCTION 
Introduction I Literature Review 
The eradication of bovine brucellosis in the United States is nearing 
completion, but research into a better vaccine continues. Besides the brucellosis issue 
in the United States, this disease also remains a problem in cattle in areas of Central 
and South America. Bruce/la spp. are a facultative intracellular bacterium 
responsible for infections in both humans and animals. One particular species, 
Bruce/la abortus (B. abortus), occurs naturally in a smooth phase. It contains a 
homopolymer of perosamine as the 0-chain component of the lipopolysaccharide 
(LPS). 1 This particular species is responsible for naturally occurring cases of 
brucellosis in cattle, bison,2•3•4 and elk,5 and also causes human brucellosis.6 Bruce/la 
abortus strain 19 (S 19), an attenuated smooth strain, was utilized in the past to 
vaccinate cattle against brucellosis.7 However, since both the S19 vaccine and 
virulent field strains occur in the smooth phase, both elicit an antibody response in 
hosts directed against their smooth LPS. Therefore, serological monitoring became 
difficult as the serological responses prevent discrimination between vaccinated and 
naturally infected animals. 8•9 
Due to this cross-reaction in serological testing it became much more difficult 
to determine the true serological status of certain animals if records were not 
complete. The development of a new vaccine which would be protective but yet not 
cross-react on standard serological tests became an important issue in bovine 
brucellosis research. 10•18 This approach to brucellosis vaccine research led to 
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investigation of rough B. abortus isolates which lack outer membrane LPS 
components which induce cross-reactions. 
After thorough investigation concerning immunological responses, efficacy, 
pathogenesis, and vaccination age effects of rough B. abortus strains, B. abortus 
strain RB51 appeared as a promising cattle vaccine candidate.10•11 •12•20•21 •22 
B. abortus strain RB51 (SRB51) is a stable rough mutant derived from B. 
abortus strain 2308 (S2308), which lacks a majority of the LPS 0-side chain. SRB51 
was derived from S2308 by repeated passage on media supplemented with rifampin 
or penicillin. 19 Due to the lack of the LPS 0-side chain no cross-reaction in standard 
serological testing exists. This allows for differentiation between animals with 
natural infections and vaccinated animals during routine screening of herds. An 
experimental dot-blot assay has been utilized for measuring serological responses to 
SRB51.23 
In addition to testing in cattle, SRB51 vaccine has also been successfully 
investigated in mice24 and goats25 concerning fetal infection from vaccination or 
SRB51 infection. SRB51 has also been included in swine studies showing protection 
against Brucella suis infection. 26 These animal studies indicate SRB51 to be less 
pathogenic than the parent strain 2308. 
In March 1996, the USDA Animal and Plant Health Inspection Service 
recognized SRB51 for utilization in calfhood vaccination. 27 With this recognition of 
SRB51 in the cattle brucellosis eradication program interest for use in other animal 
species increased. The problem of brucellosis in elk and bison could now begin 
utilizing SRB51 for investigations into control of brucellosis in these wildlife 
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reservmrs. Initial studies in bison indicated that SRB51 induced humoral and cell 
mediated immune responses.28 In addition, it was found that utilizing a vaccine dose 
similar to that used in cattle produced abortion or placentitis in pregnant bison. 29 
While overall, SRB51 appeared promising, it became evident alterations in 
vaccination schemes for a bison vaccination program would be needed. 
The increased utilization of SRB51 for vaccination programs began to lead to 
the question of stability and storage of the vaccine. The objectives of this study were 
to evaluate different stabilizing media and fill volumes for post-lyophilization 
survival of RB51 vaccine as well viability and stability during long-term storage. In 
addition, the viability at different storage conditions of a liquid RB51 vaccine was 
included. 
Strain RB51 was prepared for lyophilization at a standard concentration. 
Three different stabilizing media, World Health Organization (WHO), lactose salt 
(LS), and a WHO/LS combination, were utilized for preparing cell suspensions. 
Suspensions were bottled at two different fill volumes in preparation for 
lyophilization. Viability counts were conducted to determine post-lyophilization 
survival. Biochemical characterization of post-lyophilization cultures was also 
included to assist in determining culture stability. 
Lyophilized vaccine was stored at three different storage temperatures, 25°C, 
4°C, and -25°C for a period of fifty-two weeks. Viability of stored vaccine was 
determined every two weeks throughout the storage period. Biochemical 
characterization of vaccine cultures was also conducted. Information was obtained to 
determine the optimal storage temperatures. 
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A liquid RB51 vaccine was investigated for possible use in the future as a 
reduced dose vaccine. The liquid RB51 vaccine was prepared using three different 
bottling concentrations. After bottling, the vaccines were randomly assigned to two 
different storage temperatures. Viability and biochemical determinations were 
conducted at designated timepoints throughout the storage period. The viability and 
culture characteristics of each of the three vaccine bottling concentrations were 
compared. 
Results of the lyophilization study supplies information concerning an optimal 
stabilizing media and if fill volume influences survival of RB51 during lyophilization. 
In addition data concerning the effects of storage temperature on viability should 
assist in determining stability of RB51 vaccine for production facilitates. 
The liquid vaccine study supplies data concerning the feasibility of production 
of a liquid RBS I vaccine for use in cattle and wildlife. This information can also 
assist in determining the possible shelf life of a reconstituted RBS I lyophilized 
vaccine in clinical settings. 
Research surrounding S 19 vaccine has characterized conditions for production 
and storage as well as efficacy in cattle. With the development of new brucellosis 
vaccines this process must be repeated. Not only are animal studies essential to 
ensure optimal immunogenicity, but research into proper storage conditions plays a 
vital role in maintaining viability and effectiveness of the vaccine. 
Initially, S 19 vaccine was produced in liquid form only, but years later 
research was conducted to improve preservation of the vaccine by utilizing 
lyophilization. 30 This was the beginning of research into pursuing a more stable S 19 
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vaccme. It was apparent that S 19 could be produced using lyophilization. 30 Studies 
with lyophilized S 19 indicated the vaccine was stable for up to three years when 
stored at either refrigerated temperatures or at room temperature. 30•31 
The initial preparation of S 19 vaccine utilizing possible changes in stabilizers 
has been examined closely. The influence of various stabilizers is a major influence 
on the viability of S19 vaccine after lyophilization.32•33 Stabilizing media containing 
salts were commonly used. Some controversy existed as to whether the presence of 
salts contributed to cell death, but it was determined that the recovery of viable cells 
after lyophilization was extremely low unless salt was in the preserved suspension.34 
Due to stabilizing media research a more stable S 19 vaccine was available to 
vaccinate both female calves and adult cows. Though lyophilized vaccine proved 
more stable, monitoring of vaccine lots revealed loss of viability during shipment or 
storage. 35 A new emphasis on the effects of storage temperature was initiated. The 
stability of lyophilized S 19 vaccine at higher storage temperatures, indicated in past 
studies, was not able to be confirmed in studies re-examining this particular factor on 
vaccine viability. 35'36'37 
The National Brucellosis Eradication Program for many years concentrated on 
vaccination of female calves only. As the program expanded through the years there 
was a renewed interest in vaccinating adult cattle.37 The larger number of vaccinated 
animals made it more difficult to determine infected cattle from the vaccinated 
animals due to serological cross-reactions on standard serological tests. 8•9 This 
concern led to investigations to determine a reduced vaccine dose for both calves and 
adults in hopes of minimizing residual titers. 38•39•40•41 These reduced dosage vaccine 
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studies showed that adult cows required a dose lower than calves to establish 
satisfactory immunity. However, even with the implementation of reduced vaccine 
dosage, serological cross-reaction still existed in standard serological screening. 
Research into brucellosis vaccines then shifted towards developing vaccines 
which would not cross-react with current serological tests. Different rough mutants 
of Bruce/la abortus were examined as candidate vaccines, 10•11•12 and from this research 
one rough mutant of S2308 did emerge. This particular isolate, B. abortus RBS I, 
(RB51 ), through preliminary research in mice, rabbits, goats, and cattle showed great 
promise as a candidate for bovine brucellosis vaccination. 19 Further studies in mouse 
models 15- 17•19•21•24 and in cattle studies 10-14•20•22 showed that it could effectively be used in 
the brucellosis eradication program. 
Research using RB51 in bison revealed that bison did not clear the vaccine as 
rapidly as cattle.28•29 This problem was similar to the situation in adult cattle when it 
was necessary to used decreased vaccine dosages. The situation in bison may call for 
a reduced dose liquid vaccine in order to decrease clearance time and to maintain 
satisfactory immunologic responses. 
Studies to determine optimal production procedures for stability and viability 
of SRB51 vaccine have not been conducted to date. Since this new vaccine has been 
officially recognized for use in the brucellosis eradication program, information 
concerning stabilizers and storage temperature become more important. As studies 
continue for possible vaccine alternatives in bison and elk, data concerning the 
stability of a possible liquid vaccine will become essential. It is apparent SRB51 
7 
vaccine is an effective tool in prevention of brucellosis in cattle, and optimizing the 
production and storage of this vaccine will assist in furthering its use in other species. 
Thesis Organization 
This thesis is presented in the form of two manuscripts to be submitted for 
consideration for publication. A general conclusion section is included following the 
second manuscript. 
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SURVIVAL OF BRUCELLA ABORTUS RBSl LYOPHILIZED 
VACCINE USING DIFFERENT STABILIZING MEDIA, FILL 
VOLUMES, AND STORAGE TEMPERA TURES 
A paper to be submitted to Developments in Biological Standardization 
Randal Capsel, Steven Olsen, Norman F. Cheville, and Charles 0. Thoen 
ABSTRACT 
Lyophilized Bruce/la abortus RB51 vaccine was evaluated using three 
stabilizing mediums, two different fill volumes, and three different storage 
temperatures. Viability was determined for immediate post-lyophilization and at two-
week intervals throughout a 52-week storage period. 
There was no significant loss in viability attributed to fill volume or 
stabilizing media on immediate post-lyophilization viability. WHO and WHO/LS 
media proved most satisfactory for long-term storage of the lyophilized vaccine. A 
storage temperature of 25°C indicated a significantly rapid decline in viability 
compared to storage temperatures at 4°C and-25°C. 
Optimal storage temperatures were confirmed based on this study as well as 
the most effective stabilizers for lyophilizing RB5 l vaccine. 
INTRODUCTION 
Bruce/la abortus RBS I (RB5 l) is a new vaccine for protection against 
brucellosis in cattle. Diagnostic labs are able to differentiate between a natural 
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infection and vaccine induced immune responses in serological assays with the 
utilization of this vaccine. This vaccine recently received a conditional license for 
vaccination in cattle, and investigations by the United States Department of 
Agriculture's Research Service (ARS) are occurring to determine its suitability for 
vaccination programs with bison. 
This study was conducted to examine the effects of three conditions for the 
proper storage of lyophilized RB51 vaccine. The most suitable stabilizing media was 
investigated to determine optimal preservation of viability and biochemical 
characteristics of RBS l. A number of stabilizing mediums have been investigated 
previously, but none were found to be suitable.(1,2,3) 
In addition, the optimal storage temperature for different stabilizing media 
was determined. It has been reported that B. abortus strain 19 (S 19) was stable for 
long periods of time at lower storage temperatures of-25°C and 4°C.(4,5,6) 
The initial fill volume of the vials was another component considered for 
maximum viability preservation. This was investigated utilizing two different fill 
volumes. This study was designed to determine the optimal conditions for 
lyophilized B. abortus RB51 vaccine storage and to ensure optimal vaccine viability. 
MATERIALS AND METHODS 
Culture 
Brucella abortus RB51, (ARS-1 stock culture), was utilized for vaccine 




Phosphate buffered saline (PBS), pH 6.4, was used for harvesting bacterial 
cells from growth medium. 
One percent peptone saline (1) was used in making vaccine dilutions for 
conducting viability counts. 
Tryptose agar with 5% bovine serum (TSA) was used in plating viability 
counts. 
Tryptose agar was used for growth of seed cultures. 
Tryptose agar with 1 % extra agar was used in Roux bottles for growth of cell 
suspensions used in vaccine production. 
Stabilizing Mediums 
World Health Organization (WHO). This is the recommended stabilizing 
medium for Brucella vaccine production and lyophilization. The medium consists of 
a solution of casein, sucrose, and glutamate( I). 
Lactose Salt (LS) . This medium was initially tested for use with B. abortus 
strain 19 vaccine and has been recommended for a variety of organisms in the past. 
The medium contains 5.75% lactose and a number of inorganic and organic salts (2). 
WHO/LS. This medium is a 50/50 volume/volume combination of WHO and 
LS media. This medium was utilized to test for possible improvement over the other 
two media alone. 
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Lyophilization Apparatus 
A Virtis Consol Model 25EL, manufactured by the Virtis Company, Gardiner, 
New York, was used for lyophilization of samples. 
Vials and Closures 
The vials were made of borosilicate glass and were 10 ml in size with a 13 
mm opening. Vials were closed with silicone treated, split, butyl rubber stoppers and 
sealed with one-piece aluminum caps. 
Vaccine Preparation and Lyophilization 
An RB51 seed culture, (ARS-1), was selected and rapidly thawed. From this 
seed culture inoculums were aseptically transferred to twenty tryptose agar slants for 
initial growth and characterization. Slants were incubated for 48 hours at 3 7°C with 
5% C02. Slants were inspected for purity and harvested by adding 10 ml of PBS and 
gently agitating the agar surface with sterile plastic inoculating loops. Cell 
suspensions harvested from the slants were pooled into a large sterile flask. After all 
slants had been washed, the resulting pooled cell suspension was used to inoculate 
Roux bottles containing tryptose agar with 1 % extra agar. Each Roux bottle was 
inoculated with 10 ml of the RB51 cell suspension. Inoculated Roux bottles were 
incubated agar surface upright for two hours to allow thorough inoculum absorption 
into the agar. Roux bottles were then inverted and incubated at 37°C with 5% C02 
for 48 hours. 
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Cells were harvested from Roux bottles by gently washing the agar surface 
with 25 ml of designated stabilizing media and sterile glass beads. The cell 
suspensions from ten Roux bottles were pooled into one flask. Sterility and viability 
counts were conducted on the pooled cell suspension. The pooled suspension was 
stored at 4°C until vaccine bottling cell concentrations were determined. 
Final cell suspensions were then prepared by diluting the initial cell 
suspension with the corresponding stabilizing media. Final cell concentration was 
targeted for lx10 11 colony forming units (CFU) per vial. 
To determine the effects of fill volume on vaccine viability, vials of vaccine 
were filled with either 1 ml volumes or 3 ml volumes. Cell suspensions were diluted 
accordingly to ensure the CFU/vial remained constant. Filled vials were partially 
stoppered and frozen at -70°C for 20-24 hours within lyophilization trays . After 
freezing, lyophilization trays were transferred to the lyophilizer with shelf 
temperatures between -50°C and -60°C. Lyophilization was completed in 24 hours. 
The final temperature of the vaccine vials was between 25°C and 27°C. Vials were 
sealed while at a vacuum under 30 microns. 
Vaccine Storage 
Lyophilized vaccine from each stabilizing media and fill volume group was 
randomly assigned to storage boxes. A randomly chosen storage box from each 
group was then assigned to a designated storage temperature of either 25°C, 4°C, or -
25°C. All vials were stored in the dark and temperatures were monitored three times 
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weekly to ensure stable storage temperatures. The total storage period was 52 weeks 
for this study. 
Vaccine Evaluation 
An immediate post-lyophilization viability evaluation was conducted on three 
randomly selected vials from each vaccine group. Every two weeks during the 
storage period, three randomly selected vials from each vaccine group at each storage 
temperature were selected and evaluations conducted. The lyophilized vaccine was 
reconstituted with 10 ml of PBS and after thorough mixing examined for quality of 
cell suspension dispersion. Viability counts were conducted by withdrawing 1 ml 
from each reconstituted vial and placing in a 99 ml peptone-saline dilution blank. 
Serial dilutions to 10·7 to 10·8 from each vial were conducted. Each of five TSA 
plates was inoculated with 0.1 ml from each dilution blank. Plate spreaders were 
utilized to ensure thorough distribution of the inoculum on plates. Viability plates 
were inverted and incubated at 3 7°C with 5% C02 for five days. Colony counts were 
performed and final CFU/ml calculations carried out to give final cell numbers for 
each vial. Viability count means for each three sampling timepoints were combined 
for a total of nine timepoint means. The means between treatment groups were 
compared by a least significant difference procedure (P<0.05). 
Cultures from viability plates were utilized for testing of sterility, biochemical 
stability, and colonial morphology. 
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RESULTS 
It was immediately noted during harvest of cell suspensions for vaccine 
production that the RB51 cell suspensions rapidly autoagglutinated. The 
autoagglutination was similar for all three different stabilizing media. After final cell 
suspensions were made for bottling of the vaccine agglutinated cells in the 
suspensions appeared to readily disperse. 
The viable count of each bottled cell suspension, the postlyophilization viable 
count, and the percent survival postlyophilization can be found in Table 1. The 
average maximum loss in viability due to the lyophilization process was 12 percent. 
All stabilizing media performed satisfactorily for maintaining viability of the 
lyophilized vaccine. The two stabilizing media combinations, producing the best 
results, were the WHO/LS combination bottled at three milliliters per vial and the 
WHO media bottled at three milliliters per vial. The remaining stabilizing media and 
fill volume combinations were not significantly different from each other (P<0.05). 
Only the WHO/LS three milliliter bottling combination was significantly better than 
the remaining combinations (P<0.05). 
Evaluation of vaccine viability revealed that all vaccines rehydrated easily and 
the cells dispersed into a uniform suspension within 30 seconds. Due to problems 
with the lyophilizer sealing apparatus during one run, an occasional vial was found 
during rehydration to only have a partial vacuum. The cell suspension in these vials 
did not rehydrate differently and the cell suspensions appeared uniform. 
The viability results during storage for each vaccine group and comparisons 
between groups at the different temperatures and timepoints are summarized in 
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Figures 1-6. The overall trend indicated that the WHO stabilizer provided optimal 
protection with storage temperatures at 4°C and-25°C. Differences between fill 
volumes when comparing each stabilizer were not significant (P<0.05). The 
stabilizing media maintained cell viability similarly whether at a 1 ml fill volume or a 
3 ml fill volume. 
There was not a significant difference (P<0.05) between groups of vials with a 
1 ml fill volume stored at either 4°C or-25°C at timepoints one (0-4wk storage) and 
two (6-lOwk storage). Stabilizing media containing WHO, either alone or in 
combination with LS, resulted in the best maintenance of viability. At these early 
timepoints vaccine stabilized with LS indicated a decrease in viability, especially 
when stored at 25°C or 4°C. At timepoint four (l 8-22wk storage), all vials stored at 
25°C had significantly less viability (P<0.05) than those of the other storage groups. 
The 1 ml fill volume vials at timepoint six (30-34wk storage) showed a 
significant difference (P<0.05) at all the storage temperatures. All vials stored at 
25oC were below forty percent viability. At this time, sampling of vials stabilized 
with LS, was discontinued because of a low viability. Vials stored at -25°C 
maintained viability counts significantly higher (P0.05) than those at the other two 
storage temperatures. The vials stored at 4°C revealed satisfactory viability with at 
least seventy-five percent viability. 
At timepoints seven (36-40wk storage) and eight (42-46wk storage) all 
vaccines stored at -25°C maintained the best viability. The WHO stabilized vaccine 
maintained significantly higher viability (P<0.05) at -25°C when compared to all 
other vaccines stored at 4°C and 25°C. 
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At timepoint nine ( 48-52wk storage) the trend for viability preservation 
remained. The WHO and WHO/LS media with storage at -25°C resulted in the best 
maintenance of viability. The LS stabilized vaccine stored at-25°C maintained high 
viability, but was significantly less (P<0.05) than that resulting with WHO. Vaccine 
stored at 4°C and stabilized with WHO or WHO/LS maintained sufficient viability for 
vaccine use and was significantly better (P<0.05) than the LS stabilized vaccine 
stored at the same temperature. 
Vaccine bottled at 3 ml per vial had a similar trend as those of the 1 ml fill 
volume vials. At timepoint one sampling (0-4wk storage) the stabilizers containing 
WHO maintained the highest viability. Optimal storage temperatures were identified 
as 4°C and-25°C for viability maintenance. Vials stored at -25°C and stabilized with 
LS maintained significantly less viability (P<0.05) when compared to either the 
WHO or WHO/LS stabilizer. All LS stabilized vaccines at the 3ml fill volume 
resulted in the lowest viability maintenance at this early timepoint. 
At the second timepoint ( 6-1 Owk storage) all vaccines stabilized with WHO or 
WHO/LS were providing the highest viability. The WHO and WHO/LS stabilized 
vaccines stored at either -25°C or 4°C maintained significantly higher (P<0.05) cell 
counts than those vaccines stored at 25°C. At this storage timepoint there was a 
noticeable decrease in viability for vials stored at 25°C. However, the WHO/LS 
stabilized vaccine stored at 25°C maintained significantly better (P<0.05) viability 
than those stabilized with LS at the same storage temperature. 
Sampling timepoint three (12-16wk storage) indicated the WHO and 
WHO/LS stabilized vaccines stored at - 25°C were significantly higher (P<0.05) in 
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cell count than all other groups. The vaccines stored at 4°C and stabilized with either 
WHO or WHO/LS also maintained sufficient viability at this storage time. The 
viability of vaccines stored at 25°C was decreasing rapidly, especially those stabilized 
with LS. The LS stabilized vaccines stored at 4°C or 25°C maintained significantly 
less (P<0.05) viability than any other vaccine groups. 
At timepoints four (18-22wk storage) and five (24-28 wk storage) the vaccine 
stabilized with WHO or WHO/LS and stored at-25°C or 4°C maintained a viability 
significantly higher (P<0.05) than the other storage temperature and stabilizer groups. 
WHO stabilized vaccine stored at 25°C did maintain a viability above 50% at this 
timepoint. A rapid decline in viability was noted for vaccines stabilized with LS and 
stored at temperatures of 4°C or 25°C. The LS 25°C group maintained significantly 
less (P<0.05) viability than the other groups. 
Sampling timepoints six (30-34wk storage), seven (36-40wk storage), eight 
(42-46 week storage), and nine (48-52wk storage) indicated the same general trend 
for maintenance of viability. Vaccines stabilized with WHO or WHO/LS and stored 
at -25°C had the highest cell counts and best percent survival. The vaccines stored at 
4°C and stabilized with WHO or WHO/LS maintained sufficient viability throughout 
these timepoints; however, this viability was significantly (P<0.05) less than those 
stored at -25°C. The vaccines stored at 25°C were well below percent survival levels 
to ensure an effective vaccine remained. 
When comparing the fill volume effects on viability maintenance there were 
no overall significant trends noted. A summary of the correlation between the two 
different fill volumes is located in Table 2. The most notable item was the 3ml fill 
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volume vaccines stabilized with LS, and stored at 25°C, resulted in significantly less 
(P<0.05) viability compared to all other groups. 
The biochemical characteristics of RB51 were maintained throughout the 
entire evaluation period. Crystal violet staining of colonies on selected plates from 
each timepoint indicated that RB51 maintained rough outer membrane characteristics 
throughout the study. Urease production was positive at two hours and hydrogen 
sulfide production was evident at 24 hours. Maintenance of rifampin resistance was 
evident by colony growth on plates containing 200 ug/ml of rifampin. Colonies were 
catalase positive. Growth was recorded on plates containing penicillin. The cultures 
also grew in the presence of 1 :25000 basic fuchsin and thionine blue. There was no 
growth recorded on media containing 1: 100,000 thionin. 
DISCUSSION 
These studies indicate a significant difference in the ability of three stabilizing 
media to maintain optimal viability of RB51 during long-term storage. All media 
were easily rehydrated and did not affect the homogeneity of the vaccine suspension. 
No significant differences in viability were observed from the lyophilization 
process or between the different stabilizing media, but stabilizing media containing 
LS did give better immediate post-lyophilization results. These results were offset 
though by the poor performance evident as storage periods were extended. 
The stabilizing media that provided the highest viability for long-term storage 
was the WHO medium or a medium containing a combination of WHO and LS. 
These particular media maintained the highest viability throughout all storage 
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temperatures. In contrast, the LS stabilizing media alone was the least effective at the 
different storage temperatures, especially at higher storage temperatures. 
This study provided additional evidence that lyophilized brucella vaccines 
should be stored at a maximum temperature of 4°C. Previous studies have indicated 
an identical trend for maintaining optimal vaccine viability (5,6). This has been a 
common storage temperature for most brucellosis vaccines (1,4,5,6) and is no 
different for the RB51 vaccine. Utilizing WHO-containing stabilizing media it is 
possible to store RB51 vaccine at -25°C without an observed decrease in vaccine 
viability. 
The occasional vials, which gave viability counts higher than 100% survival, 
likely resulted from the rapid autoagglutination of RB51. It became evident during 
the bottling process that the stirring action must be sufficiently maintained to disrupt 
clumps of cells which already exist, as well as avoid further agglutination. It is likely 
during this bottling process that stirring was not sufficient, and due to the slow 
bottling process may have allowed some autoagglutination to occur. 
Approximately 20% of the vials were found throughout the evaluation process 
to have only partial vacuums. During one of the stoppering processes the shelves 
were not raised evenly and these vials were not sealed completely under vacuum. An 
attempt to regain a vacuum in the lyophilizer was not successful and it was decided to 
utilize the vials without a complete vacuum within the study. It would appear that 
even under less than ideal conditions the RB51 vaccine still maintained sufficient 
viability when stored under proper conditions. 
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The importance of fill volume effects on this particular vaccine was not 
evident. This may be due to the effectiveness of the stabilizing media. The rough 
outer membrane characteristic of RB51 (7) may also assist in maintaining viability. 
With the high level of autoagglutination that occurs, it is very likely that the outer 
layer of cells of the agglutinated mass offer protection for cells near the middle of the 
mass. This thought stems from the theory that the cells on the outer edge of the 
agglutinated mass would be exposed to the most harsh conditions from freezing and 
lyophilization processes. The cells further within the mass may be exposed the 
actions of freezing and lyophilization in a more gradual fashion. 
There was no evidence of reversion to smooth cultural characteristics 
throughout the entire study. This, along with the biochemical characteristics 
recorded, indicate that RB5 l maintains its stability during all of the storage 
temperatures and conditions tested. This observation further emphasizes the 
suitability ofRB51 for use as a vaccine in brucellosis vaccination programs. 
It may be feasible for a future study to analyze storage periods longer than one 
year. In addition, since there is very little loss in viability, the concentration of cells 
initially bottled may be able to be decreased. A study involving cell bottling 
concentration may produce data that would allow vaccine producers to utilize an 
RB51 batch at lower bottling concentrations resulting in increased bottling numbers. 
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Table 1: Survival of Brucella abortus RB51 Vaccine in Three Stabilizing Media Post-
Lyophilization 
Fill Stabilizing Pre-Lyophilization Post-Lyophilization % Survival 
Volume Media a Count {CFU/ml} Count {CFU/ml} 
1 ml 
Trial 1 WHO 11.3xl010 9.98xl010 88.3 
LS 11.7x1010 10.60x1010 90.6 
WHO/LS 10.4x1010 10.20x1010 97.6 
Trial 2 WHO 9.88x1010 9.4x1010 95.1 
LS 6.04xl010 6.47x10 10 107 
WHO/LS 8.86xl010 10.00x1010 112.9 
3 ml 
Trial 1 WHO 7.2x1010 7.89x1010 109 
LS 8.4x1010 7.85x1010 93.4 
WHO/LS 7.5x1010 11.00x1010 146 
Trial 2 WHO 9.36xl0 10 10.50xl010 112 
LS 8.46x1010 9.10xl010 107 
WHO/LS 15.00xl010 13 .20xl010 88.0 
a = stabilizing media designations as follows : WHO - World Health Organization, LS - Lactose Salt, 
WHO/LS - 50150 v/v combination of WHO and LS 
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Table 2: Comparison of Viability of Brucella abortus RB51 for Three Media Using 
Different Fill Volumes 
TimeEoint: 1 Stabilizing Media and Storage Temperatures" 
l ml 
3ml W25 W4 W-25 L25 L4 L-25 WL25 WL4 WL-25 
W25 NS NS NS NS NS NS NS *< NS 
W4 NS NS NS *> NS NS NS NS NS 
W-25 *> *> *> *> *> *> *> NS *> 
L25 *< *< *< *< *< *< *< *< *< 
L4 *< *< *< NS *< *< *< *< *< 
L-25 *< *< *< NS NS *< NS *< *< 
WL25 NS NS NS *> NS NS NS NS NS 
WL4 NS NS NS *> NS NS NS NS NS 
WL-25 NS NS NS *> *> NS NS NS NS 
TimeEoint: 2 
lml 
3ml W25 W4 W-25 L25 L4 L-25 WL25 WL4 WL-25 
W25 *< *< *< NS *< *< *< *< *< 
W4 NS NS NS *> *> NS *> NS NS 
W-25 *> *> *> *> *> *> *> *> *> 
L25 *< *< *< *< *< *< *< *< *< 
L4 *< *< *< NS *< *< *< *< *< 
L-25 *< *< *< *> NS *< *< *< *< 
WL25 *< *< *< *> NS *< *< *< *< 
WL4 *> *> *> *> *> *> *> *> *> 
WL-25 *> NS NS *> *> *> *> *> *> 
TimeEoint: 3 
lml 
3ml W25 W4 W-25 L25 L4 L-25 WL25 WL4 WL-25 
W25 NS *< *< *> *< *< NS *< *< 
W4 *> *< *< *> NS *< *> *< *< 
W-25 *> *> NS *> *> NS *> *> NS 
L25 *< *< *< *< *< *< *< *< *< 
L4 *< *< *< NS *< *< *< *< *< 
L-25 NS *< *< *> *< *< NS *< *< 
WL25 NS *< *< *> *< *< NS *< *< 
WL4 *> NS NS *> NS *< *> NS *< 
WL-25 *> NS NS *> *> NS *> NS NS 
NS = not significantly different; *> = 3ml fill vol. significantly higher viability than lml fill volume; 
*< = 3ml fill volume significantly lower viability than Im! fill volume. 
a= Stabilizing media designations as follows: W - World Health Organization (WHO), L - Lactose Salt 
(LS), WL- 50/50 v/v combination of WHO and LS 
28 
Table 2 (continued) 
Timepoint: 4 
lml 
3ml W25 W4 W-25 L25 L4 L-25 WL25 WL4 WL-25 
W25 NS *< *< *> *< *< *> *< *< 
W4 *> *< *< *> NS *< *> *< *< 
W-25 *> NS *< *> *> *< *> NS *< 
L25 *< *< *< *< *< *< *< *< *< 
L4 *< *< *< NS *< *< NS *< *< 
L-25 *> *< *< *> *< *< *> *< *< 
WL25 NS *< *< *> *< *< *> *< *< 
WL4 *> NS *< *> *> *< *> NS *< 
WL-25 *> *> NS *> *> *< *> NS NS 
Timepoint: 5 
lml 
3ml W25 W4 W-25 L25 L4 L-25 WL25 WL4 WL-25 
W25 NS *< *< *> NS *< *> *< *< 
W4 *> *< *< *> *> *< *> NS *< 
W-25 *> *> NS *> *> *> *> *> NS 
L25 *< *< *< *< *< *< *< *< *< 
L4 *< *< *< *> *< *< NS *< *< 
L-25 NS *< *< *> NS *< *> *< *< 
WL25 *< *< *< *> *< *< NS *< *< 
WL4 *> NS *< *> *> NS *> NS *< 
WL-25 *> NS *< *> *> NS *> *> *< 
Timepoint: 6 
lml 
3ml W25 W4 W-25 L25 L4 L-25 WL25 WL4 WL-25 
W25 NS *< *< *> *< *< *> *< *< 
W4 *> NS *< *> NS *< *> NS *< 
W-25 *> *> NS *> *> NS *> *> *< 
L25 
L4 *< *< *< NS *< *< NS *< *< 
L-25 *> *< *< *> *< *< *> *< *< 
WL25 *< *< *< NS *< *< NS *< *< 
WL4 *> NS *< *> NS *< *> NS *< 
WL-25 *> *> NS *> *> NS *> *> NS 
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Table 2 (continued) 
Timepoint: 7 
lml 
3ml W25 W4 W-25 L25 L4 L-25 WL25 WL4 WL-25 
W25 NS *< *< *< *< *> *< *< 
W4 *> *< *< NS *< *> NS *< 
W-25 *> *> NS *> NS *> *> NS 
L25 
L4 NS *< *< *< *< NS *< *< 
L-25 *> *< *< NS *< *> *< *< 
WL25 *< *< *< *< *< NS *< *< 
WL4 *> NS *< *> *< *> NS *< 
WL-25 *> *> *< *> NS *> *> NS 
Timepoint: 8 
lml 
3ml W25 W4 W-25 L25 L4 L-25 WL25 WL4 WL-25 
W25 NS *< *< *< *< NS *< *< 
W4 *> *< *< NS *< *> NS *< 
W-25 *> *> NS *> *> *> *> NS 
L25 *< *< *< *< *< *< *< *< 
L4 *> *< *< NS *< *> *< *< 
L-25 *> NS *< *> NS *> *< *< 
WL25 NS *< *< *< *< NS *< *< 
WL4 *> NS *< *> *< *> NS *< 
WL-25 *> *> NS *> *> *> *> NS 
Timepoint: 9 
lml 
3ml W25 W4 W-25 L25 L4 L-25 WL25 WL4 WL-25 
W25 NS *< *< NS *< *< NS *< *< 
W4 *> NS *< *> *> *< *> *> *< 
W-25 *> *> *< *> *> *> *> *> NS 
L25 *< *< *< NS *< *< NS *< *< 
L4 *> *< *< *> NS *< *> *< *< 
L-25 *> *> *< *> *> NS *> *> *< 
WL25 NS *< *< NS *< *< *> *< *< 
WL4 *> NS *< *> *> *< *> NS *< 
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Figure 1: Average percent survival of lyophilized Bruce/la 
abortus RB51 vaccine stabilized with World Health 
Organization (WHO) media, Lactose Salt (LS) media, or 
WHO/LS (50/50 v/v) at a lml fill volume and stored at 25°C. 
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Figure 2: Average percent survival of lyophilized Brucel/a 
abortus RB51 vaccine stabilized with World Health 
Organization (WHO) media, Lactose Salt (LS) media, or 
WHO/LS (50/50 v/v) at a lml fill volume and stored at 4°C. 
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Figure 3: Average percent survival of lyophilized Brucella 
abortus RB51 vaccine stabilized with World Health 
Organization (WHO) media, Lactose Salt (LS) media, or 
WHO/LS (50/50 v/v) at a lml fill volume and stored at -25°C. 
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Figure 4: Average percent survival of lyophilized Bruce/la 
abortus RB51 vaccine stabilized with World Health 
Organization (WHO) media, Lactose Salt (LS) media, or 
WHO/LS (50/50 v/v) at a 3ml fill volume and stored at 25°C. 
·····+ ····· WHO 
-0--LS 
····b-··· WHO/ L S 
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Figure 5: Average percent survival of lyophilized Brucella 
abortus RB51 vaccine stabilized with World Health 
Organization (WHO) media, Lactose Salt (LS) media, or 
WHO/LS (50/50 v/v) at a 3ml fill volume and stored at 4°C. 
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Figure 6: Average percent survival of lyophilized Bruce/la 
abortus RB51 vaccine stabilized with World Health 
Organization (WHO) media, Lactose Salt (LS) media, or 
WHO/LS (50/50 v/v) at a 3ml fill volume and stored at -25°C. 
····+ ····· WHO 
-0- LS 
··· " WHO/ LS 
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SURVIVAL OF Brucella abortus RB51 LIQUID VACCINE UNDER 
DIFFERENT STORAGE TEMPERATURES 
A paper to be submitted to Developments in Biological Standardization 
Randal Capsel, Steven Olsen, Norman F. Cheville, Charles 0. Thoen 
ABSTRACT 
Liquid Brucella abortus RB51 vaccine lots were prepared and evaluated using 
three different bottling concentrations. The vaccines were then distributed equally at 
two different storage temperatures and viability determinations were conducted at 
designated timepoints throughout the storage period. These three vaccines were 
compared based on their ability to retain distinguishing cultural characteristics and to 
maintain viability at different storage temperatures. 
The higher storage temperature showed a more rapid decline in viability. In 
addition, the vaccines bottled at higher cell concentrations maintained a higher 
percent viability than the lower cell concentration bottlings. The vaccine maintained 




Brucella abortus RB5 l (RB51) is a new vaccine utilized for brucellosis 
protection in cattle. This new vaccine allows labs to differentiate between a natural 
infection and vaccine induced responses in serological testing. The lyophilized 
vaccine recently received a conditional license for cattle vaccination, and 
investigations by the United States Department of Agriculture's Agricultural 
Research Service are occurring to determine its suitability for vaccination programs 
with bison. Initial investigations indicate that RB51 vaccine persists in bison longer 
than cattle.(1,2) For this reason, lower dose effectiveness and vaccine persistence will 
play a major role in future bison vaccination testing. 
Brucella abortus strain 19 (S 19) liquid vaccine has been evaluated in the 
past.(3,4) B. abortus S 19 is a smooth brucella strain; therefore it is possible that 
RB51 may have different storage characteristics in the form of a liquid vaccine. 
This study was conducted to examine the effect of two storage temperatures 
on the viability and cultural characteristics of RB51 liquid vaccine. A reduced dose 
vaccine may need to be utilized for bison vaccination; therefore it was of interest to 
examine the stability of liquid RB51 vaccine at different storage temperatures. A 
liquid vaccine is of interest due to the ease of immediate dilution being performed at 
the time of vaccination depending upon the age and type of animal being vaccinated. 
This would be an extremely useful vaccine in the case of bison vaccination where the 
dosage may need to be reduced. Since storage temperatures and duration are 
sometimes difficult to determine after a vaccine's initial use, two common storage 
temperatures which might be encountered in field and/or clinical conditions were 
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selected for this initial study. A two week and four week storage period were the two 
primary storage lengths examined during this study. 
MATERIALS AND METHODS 
Culture 
Brucella abortus RBS l , ARS-1 stock, was utilized for vaccine production 
seed and has typical characteristics differentiating RB51 from other Brucella strains. 
Mediums 
Phosphate buffered saline (PBS), pH 6.4, was used for harvesting bacterial 
cells and for dilution of cell suspensions for correct bottling concentrations. 
One percent peptone saline (5) was used in making vaccine dilutions for 
conducting viability counts. 
Tryptose agar with 5% bovine serum (TSA) was used for plating viability 
counts. 
Tryptose agar was used for growth of seed cultures. 
Tryptose agar with 1 % extra agar was used in Roux bottles for vaccine cell 
production. 
Vials and Closures 
The vials were made of borosilicate glass and were 10 ml in size with a 13 
mm opening. Vials were closed with silicone treated butyl rubber stoppers and sealed 
with one piece aluminum caps. 
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Vaccine Preparation 
An RB51 seed culture, ARS-1 , was selected and rapidly thawed. Inoculums 
from the seed culture were aseptically transferred to 20 tryptose agar slants. Slants 
were incubated for 48 hours at 37°C with 5% C02 . Slants were inspected to ensure 
pure growth and cells were harvested by adding 10 ml of PBS to each tube. The agar 
surface was gently agitated with a sterile plastic inoculation loop. Cell suspensions 
harvested from the slants were pooled into a sterile flask. After harvesting cells from 
all slants, the final pooled suspension was used to inoculate Roux bottles containing 
tryptose agar with 1 % extra agar. Roux bottles were inoculated with 10 ml each of 
the pooled suspension. Roux bottles were incubated for two hours with the agar 
surface upright to ensure maximum absorption of the inoculum. After two hours the 
Roux bottles were inverted and incubated at 3 7°C with 5% C02 for 48 hours . 
Cells were harvested from the Roux bottles by gently washing the agar surface 
with 25 ml of PBS and sterile glass beads. The cell suspensions from ten Roux 
bottles were pooled into one flask. Sterility and viability counts were conducted on 
the pooled cell suspensions. 
The final cell suspension was prepared after determining the initial cell 
concentration from viability counts. The initial cell suspensions were diluted with 
PBS to give final concentrations of 5x109 CFU/ml, lx109 CFU/ml, and 5x108 
CFU/ml. With constant stirring of the diluted cell suspension, each of the vials was 
filled with a 5-ml volume and immediately stoppered and sealed with aluminum 
seals. After all vials were filled viability counts were conducted on the final diluted 
suspensions used to fill vials. 
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Vaccine Storage 
Filled vials from each of the three cell concentration groups were randomly 
assigned to two storage boxes to give an equal distribution at each storage 
temperature. One storage box for each group was placed in a refrigerator maintained 
at 4°C and the second box for each group was stored in a storage drawer maintained 
at room temperature (25°C). Temperatures had been monitored daily in each storage 
area for one week prior to storage and continued to be monitored three times weekly 
during the entire study. All vials were stored in the dark. 
Vaccine Evaluation 
Evaluation of the liquid vaccine was conducted on three randomly selected 
vials from each storage temperature in each cell concentration group. Group 
designations for evaluation was as follows: Group I - 5x109 CFU/ml, Group 2 -
lxl09 CFU/ml, and Group 3 - 5x108 CFU/ml. All evaluations for a given storage 
temperature and time were conducted at the same time. After thorough mixing, each 
vial was examined for quality of cell suspension dispersion. Viability counts for each 
vial were conducted by withdrawing I ml from the vial and placing in a 99 ml 
peptone-saline dilution blank. After thorough mixing of each blank, serial dilutions 
were continued to a final dilution of 10-7 or 10-8• Each of five TSA plates was 
inoculated with 0.1 ml from each dilution blank. Inoculums were evenly spread 
across the plate surface and plates were inverted for incubation at 37°C with 5% C02 
for five days. Colony counts were performed and final CFU/ml calculations 
performed to give final cell numbers for each vial. Values from each trial were 
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combined for an overall group mean for the purpose of statistical calculations. The 
means between treatment groups were compared by a least significant difference 
procedure. 
The first trial was extended beyond the four week timepoint to determine a 
possible endpoint for vaccine viability when stored under less than ideal conditions. 
Selected colonies from viability plates were utilized for biochemical 
characterization to test the biochemical cultural stability of the vaccine. 
RESULTS 
The cell suspensions harvested for vaccine production quickly 
autoagglutinated. With sufficient agitation the agglutinated cells were dispersed into 
a uniform suspension. Concentration of cell suspensions to the desired cell 
concentrations were more easily accomplished due to this autoagglutination. The 
agglutinated cell mass at the bottom of flasks was sufficiently stable so that excess 
PBS could be withdrawn from the flask without disturbing the cells. 
The percent survival for each vaccine during the different sampling times is 
summarized in Table 1. Overall, the viability of liquid vaccine stored at 4°C 
maintained excellent viability during the entire storage period. Vaccines stored at 
25°C maintained suitable viability for a short storage period, but rapidly declined as 
time was extended. 
At four days storage, there was no significant difference (P<0.05) between 
storage temperatures in maintaining viability. Effects of different cell concentrations 
during bottling were not evident at this sampling time. 
- - - -- - --- - ~-----~---
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No significant difference (P<0.05) was noted between storage groups at seven 
days post storage. All vaccines maintained excellent viability. At the two week 
storage period there was again no significant difference (P<0.05) in percent survival 
between all vaccine groups. The vaccines stored at 4°C maintained higher viabilities 
than those stored at 25°C. 
At four weeks storage, the vaccines stored at 4°C all were significantly higher 
(P<0.05) in percent survival than those stored at 25°C. The one exception was the 
vaccine bottled at 5x109 CFU/ml. This particular vaccine maintained viability which 
was not significantly different (P<0.05) from the vaccines stored at 4°C. 
The vaccines stored at 25°C all rapidly declined in percent survival by the 
eight week sampling timepoint. All three 25°C vaccine groups were below 50% 
survival on viability counts. At this sampling time the vaccine bottled at 5x108 
CFU/ml and stored at 4°C maintained the best viability and was not significantly 
different (P<0.05) from that bottled at a concentration of 5x109 CFU/ml and stored at 
4oe, 
The longest storage period tested, 12 weeks, indicated evidence that RB51 
liquid vaccine stored at room temperature will no longer maintain sufficient viability. 
All three vaccine groups at 25°C were below 10% viability from the original bottling 
counts. In contrast, all three vaccine groups stored at 4°C maintained excellent 
viability. There was no significant difference (P<0.05) between the vaccines stored at 
4°C. Figures 1-4 illustrate the general trends in percent survival and show 
comparisons between the bottling concentrations. 
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The biochemical characteristics of RB51 were maintained throughout the 
entire evaluation period. Crystal violet staining of colonies on selected plates from 
each timepoint indicated that RB51 maintained rough outer membrane characteristics 
throughout the study. Urease production was positive at two hours and hydrogen 
sulfide production was evident at 24 hours. Maintenance of rifampin resistance was 
evident by colony growth on plates containing 200 ug/ml of rifampin. Colonies were 
catalase positive. Growth was also recorded on plates containing penicillin. The 
cultures also grew in the presence of 1 :25000 basic fuchsin and thionine blue. There 
was no growth recorded on media containing 1: 100,000 thionin. 
DISCUSSION 
The feasibility of liquid RB51 vaccine production initially appears promising. 
The cell suspensions were easily produced, and if further cell concentration was 
needed the autoagglutination of the cells allowed for reduction of suspension volume 
without centrifugation. It was found that the agitation during vaccine bottling must 
be sufficient to disperse pre-existing cell clumps as well as prevent formation of 
further agglutination. This rapid agglutination may explain the percent survival 
counts above 100% revealed from vaccine bottle plate counts. 
When stored at 4 °C, differences due to bottling concentrations did not appear 
to be a factor. With the rapid autoagglutination it would seem a higher bottling 
concentration might allow for a greater percent survival during longer storage 
periods. This was evident in the vaccines stored at 25°C. Vaccines bottled at higher 
cell concentrations and stored at 25°C resulted in higher percent survival when 
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compared to the lower cell concentrations. However, this difference was not 
significant. 
In addition, this study lends support as to proper storage conditions for 
rehydrated lyophilized RB51 vaccine. Typically, in many large animal practices, 
once a vaccine is rehydrated it is completely utilized during that visit. However, there 
may be times when a partial bottle is either transported between visits or stored within 
the clinic. During these times it is important to be aware of storage conditions, 
especially when travelling between visits. From these results it indications are that a 
rehydrated bottle of lyophilized RB51 vaccine would still maintain optimal viability 
for short period of time if not stored in ideal conditions. It was evident though that 
any improper long-term storage will result in a very rapid decline in viability 
resulting in an ineffective vaccine. 
A reduced dose vaccine for possible use in bison vaccination programs may 
prove useful in the future. Reliable viable cell counts conducted upon vaccine 
bottling would allow a calculated diluent volume to be added to a vaccine bottle, 
resulting in the desired reduced dose vaccine. If studies determine these reduced 
doses in bison are effective and safe, a liquid vaccine would offer a more exact cell 
concentration upon which to base vaccine dose. 
Future research may focus upon a longer storage period for vaccine stored at 
4°C. Viability may be maintained for longer periods oftime than 12 weeks, 
especially if bottled at a higher cell concentration. 
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Table 1: Percent Survival of Bruce/la abortus RB5 l Liquid Vaccine 
Storage Storage Time 
Tem~erature 
25°C 4 day 7 day 2 week 4 week 8 week 12 week 
Gr.I -Trial 1• 103.19 128.55 99.34 98.27 33.47 8.95 
Gr.I -Trial 2 95.85 90.82 95.35 91.07 
Gr.2 - Trial 1 b 111.93 115.79 110.88 67.02 9.47 1. 14 
Gr.2 - Trial 2 89.29 86.67 87.07 77.51 
Gr.3 - Trial 1 c 133.64 122.22 112.04 53.01 3.09 .68 
Gr.3 - Trial 2 80.90 75.13 73.33 69.87 
4°C 
Gr. l - Trial l 120.05 130.81 117.40 108.63 106.91 104.65 
Gr. I - Trial 2 102.77 89.18 87.92 94.84 
Gr.2 - Trial 1 119.09 113.68 120.49 113.33 100.56 107.65 
Gr.2 - Trial 2 95.02 82.36 96.77 91.65 
Gr.3 - Trial 1 118.52 122.22 133.18 118.67 102.93 101.39 
Gr.3 - Trial 2 90.38 79.23 75 .77 76.92 
a = Group 1 - 5x109 CFU/ml bottling concentration; b =Group 2 - lx109 CFU/ml bottling 
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Figure 1: Average percent survival of trial 1 Brucel/a abortus 
RB51 liquid vaccine bottled at three different cell 
concentrations and stored at 25°C. Group 1 was bottled at 
5xl09 CFU/ml, group 2 at lxl09 CFU/ml, and group 3 at 
5xl08 CFU/ml 
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Figure 2: Average percent survival of trial 2 Brucella abortus 
RBSl liquid vaccine bottled at three different cell 
concentrations and stored at 25°C. Group 1 was bottled at 
5x109 CFU/ml, group 2 at lxl09 CFU/ml, and group 3 at 
5xl08 CFU/ml 
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Figure 3: Average percent survival of trial 1 Bruce/la abortus 
RB51 liquid vaccine bottled at three different cell 
concentrations and stored at 4°C. Group 1 was bottled at 
5xl09 CFU/ml, group 2 at lxl09 CFU/ml, and group 3 at 
5x108 CFU/ml 
-···+-·-· Gr o up I 
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Figure 4: Average percent survival of trial 2 Bruce/la abortus 
RB51 liquid vaccine bottled at three different cell 
concentrations and stored at 4°C. Group 1 was bottled at 
5x109 CFU/ml, group 2 at lxl09 CFU/ml, and group 3 at 
5xl08 CFU/ml 
--+-··- Group I 
-D-Group 2 
···A··· Group 3 
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GENERAL CONCLUSIONS 
The ability to vaccinate animals against brucellosis and differentiate 
serologically between vaccinated and naturally infected animals has plagued the 
brucellosis eradication program since its inception. The development of the new 
RB51 vaccine allows for this differentiation. Standard serological assays routinely 
used for brucellosis monitoring have showed no cross-reaction with serum from 
vaccinated animals. For this reason RB51 contributes greatly to continuing the 
eradication program. 
Developing a new vaccine and determining the best route of vaccination as 
well as vaccine production is a detailed process. Unfortunately, if a vaccine is not 
stabilized properly during production procedures, the time and effort put into animal 
studies will have little value. Optimal preservation methods for B. abortus strain 19 
(S 19) have been researched for years. However, due to the differences between 
smooth S 19 and rough RB51 , the optimal stabilizing and storage conditions for RB51 
were unknown. Recommendations for vaccine storage are mostly at refrigerated or 
frozen temperatures. This background presented an initial optimal storage 
temperature for study. Information concerning stability under less than ideal 
conditions is also useful. 
The first portion of this study was designed to determine optimal stabilizing 
media as well as storage temperature for lyophilized RB51 vaccine. Three stabilizing 
media were tested for viability maintenance as well as retaining biochemical cultural 
characteristics. The three storage temperatures, in combination with stabilizing 
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media, played a large role in maintaining vaccine viability. A stabilizing media 
containing either WHO alone, or in combination with LS, proved effective in 
maintaining the stability and viability of lyophilized RB51 vaccine. As was 
suspected, a lower storage temperature permitted optimal viability maintenance for 
the vaccines. However, vaccines remaining in improper storage temperatures for a 
short period of time do not suffer a detrimental loss of viability, as the vaccines stored 
at 25°C were able to maintain sufficient cell viability for a few weeks. 
The volume of cell suspension bottled in preparation for lyophilization did not 
appear to influence viability maintenance. The rapid autoagglutination of RB51 may 
allow for vaccine bottling at higher cell concentrations and lower fill volumes. In this 
fashion the freeze-drying process will be more complete in a shorter period of time 
possibly allowing for either decreased production time or less stress on the cells 
within the vaccine. 
Lyophilized RB51 vaccine, due to its ability to survive the lyophilizing 
process well, should allow vaccine production facilities to utilize a batch tank of 
RB51 to a greater extent. Since there is such a small loss of cell viability during 
lyophilization, the concentration of RB51 that must be bottled into each vial should 
be less, allowing for production of a larger number of vials. 
The second portion of this study involved determining possible storage factors 
that may affect the eventual production of a liquid RB51 vaccine. The results, which 
have been found, with bison research and RB51 , indicate a possible problem with 
longer shedding periods in bison than are found in cattle. While this may be due to 
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physiological and/or immunologic differences in bison, it may be found that a 
reduced dose vaccine will need to be utilized for bison vaccination. 
Reduced dose brucellosis vaccines have been used in the past for vaccinating 
adult cattle. It was found that the reduced dose vaccines resulted in comparable 
immunological responses in adult cattle when compared to higher doses given to 
calves. 
Due to the possible variability in lyophilized vaccines, it is preferable to 
utilize a liquid vaccine with recent viability counts on record, for vaccinations 
requiring a reduced dose vaccine. A liquid vaccine can be quickly diluted to the 
proper concentration with a supplied diluent, allowing practitioners to administer a 
more accurate reduced dose. This study indicated that a liquid RB51 vaccine could 
be produced and maintained at refrigerated temperatures. 
The RB51 liquid vaccine must be thoroughly mixed to ensure complete 
disruption of the agglutinated cells. All the liquid vaccines went into suspension 
easily and appeared homogeneous. The vaccines maintained excellent viabilities 
when stored at refrigerated temperatures. A higher bottling cell concentration did 
appear to increase viability maintenance slightly, but was not a significant factor 
during the short storage times tested. 
As with the lyophilized vaccines, it was shown that liquid RB51 vaccine when 
stored for short periods of time at higher temperatures would maintain viability and 
stability. However, the liquid vaccine will loose viability more rapidly than the 
lyophilized vaccine, if maintained at higher temperatures for too long a period of 
time. The ability of reconstituted lyophilized vaccine to maintain viability should 
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relate directly to the liquid RB51 vaccine study. This may prove useful in clinical 
settings where vaccines are sometimes not always stored properly. 
These studies should help promote the use of RB51 vaccine. Data indicates 
RB51 to be a very stable organism, which can withstand long storage periods. 
Though the cattle eradication program is having great success, there are still concerns 
with brucellosis in bison and elk in which RB51 may be a useful tool. 
Future studies may focus on determining longer storage periods for both the 
lyophilized and liquid vaccine. Since cell concentration and fill volume during 
bottling do not affect results significantly, it may be feasible for future research to 
examine decreasing cell concentration during vaccine bottling. In turn a decrease in 
bottling volumes may occur. 
B. abortus RBS I has proven an effective vaccine in cattle studies to date, and 
the stability and ability to maintain viability only lend further support to its use in 
vaccination programs. 
